Radium-223
Ra-223 · Radium, Z = 88, A = 223
At 1.90e+15 Bq/g — 5.12e+4 Ci/g — a gigabecquerel of Ra-223 amounts to 528 ng, which is why activity rather than mass is how anyone states the quantity. Radium-223 decays by alpha emission with a half-life of 11.43 days, falling to 65.41% of today's activity in a week and 0.40% in three months.
The air kerma rate constant recorded for Ra-223 is 0.0159 mGy·m²/(GBq·h), and the dose rates in the table are for that emission alone. No ranking against the other emitters here is drawn: for most of them the constant is the whole field, and for Ra-223 it is not.
The two columns of the line table disagree here: the 269.5 keV line carries the largest share of the dose rate although the 83.8 keV line is emitted more often — energy, not frequency, decides which photons set the shield.
For Ra-223's own photons, 0.628 mm of lead halves the air kerma rate, 4.42 mm if the material is steel, and 4.03 mm of lead takes it to a tenth. What thickness the source in front of you needs is a question about its chain, not about this line list. The tenth-value layer runs 6.4 times the half-value layer, not the 3.32 a single energy would give.
These photon figures are Ra-223's own. What it decays into is not in this dataset, so nothing below Ra-223 is counted here. A source left sealed long enough for the chain to build up reads higher than this — how much higher is outside what this page can compute.
Alpha emission is led by 5.716 MeV at 51.2%, one of 12 recorded lines. None of it reaches through skin, so the alpha is an intake hazard rather than an external one — the photon figures above are the separate question.
Ra-223 bone targeting and the revision of activity standards
Ra-223 is an alpha-emitting radium isotope administered as radium dichloride for selected patients with prostate cancer involving bone. Radium behaves chemically like calcium and associates with hydroxyapatite where bone turnover is increased. This directs irradiation towards sites of skeletal disease, where short alpha tracks produce concentrated damage in nearby cells. The US indication is specifically for castration-resistant disease with symptomatic bone metastases and no known visceral metastases; it is not a general indication for every form or distribution of prostate cancer.
The decay sequence begins with Rn-219 and proceeds through short-lived descendants to stable Pb-207. Those descendants contribute radiation of their own, so the energy released by a retained decay chain exceeds that represented by the parent's alpha transitions alone. Gamma emissions accompanying the chain also make activity measurements and contamination detection possible. Clinical activity assays therefore have to be related to a defined radium standard, rather than treating a photon count as a direct measurement of alpha energy delivered to a patient's bone.
Ra-223 provides an instructive example of why measurement traceability matters. NIST discovered a discrepancy between its primary activity standard and the transfer standard used to disseminate that calibration. New primary measurements used anticoincidence and coincidence-ratio methods, with additional checks by liquid scintillation and gamma counting. These investigations led to a revised calibration factor for the secondary standard ionisation chamber. The change concerned the relationship between a measured instrument response and the activity assigned to a source, not a newly discovered decay mode or a change in the radionuclide itself.
The resulting clinical implementation changed the numerical activity stated for Xofigo and the corresponding activity per body mass. A healthcare communication explained that the actual product and the amount administered had not changed, even though the labelled numbers increased. Dose calibrators required settings consistent with the revised reference material. This distinction matters when comparing older treatment records with later product information. Separately, handling remains concerned with unsealed activity: faecal excretion is the main elimination route, and spills of bodily fluids can transfer contamination. Limited external exposure does not eliminate that pathway.
- LNHB / DDEP, Recommended nuclear data tables: Ra-223
- XOFIGO prescribing information, DailyMed, indication, decay chain, handling and pharmacokinetics
- NIST, Revision of the NIST Standard for 223Ra: New Measurements and Review of 2008 Data
- Bayer / EMA-agreed healthcare communication, Xofigo change in NIST standard reference material, archived by MHRA (2016)
Half-life, specific activity and dose rate
| Half-life | 11.43 days (9.876e+5 s) |
| Decay mode | alpha decay |
| Specific activity | 1.90e+15 Bq/g (5.12e+4 Ci/g) |
| Air kerma rate constant Γ (δ = 20 keV) | 0.0159 mGy·m²/(GBq·h) |
| Dose rate, 1 GBq at 1 m | 0.0159 mGy/h |
| Dose rate, 1 Ci at 1 m | 0.586 mGy/h |
| Kerma-weighted mean photon energy | 222.2 keV |
56 lines above the cutoff, and what each contributes
3 further lines below the 20 keV cutoff, the highest at 14.40 keV and 23.0% emission probability in all, are excluded here and from Γ. Probability and dose share.
| Energy (keV) | Emission probability (%) | Share of dose rate (%) |
|---|---|---|
| 269.46 | 13.3042 | 29.25 |
| 83.79 | 25.4 | 14.73 |
| 323.87 | 3.6421 | 9.88 |
| 81.07 | 15.42 | 8.70 |
| 338.28 | 2.60064 | 7.40 |
| 154.21 | 6.02 | 6.75 |
| 94.88 | 8.82 | 5.68 |
| 445.03 | 1.21845 | 4.64 |
| 144.24 | 3.47354 | 3.60 |
| 97.53 | 2.82 | 1.86 |
| 371.68 | 0.43464 | 1.37 |
| 122.32 | 1.30453 | 1.11 |
| 158.63 | 0.73805 | 0.86 |
| 328.38 | 0.20227 | 0.56 |
Showing the 14 largest contributors of 56 lines above the cutoff; the remainder together carry 3.62% of the dose rate.
0.628 mm of lead halves this spectrum
Solved numerically across all 56 lines, narrow beam. Why not one representative energy.
| Material | HVL (mm) | TVL (mm) | TVL / HVL |
|---|---|---|---|
| lead | 0.628 | 4.03 | 6.41 |
| tungsten | 0.346 | 2.92 | 8.43 |
| iron | 4.42 | 20.8 | 4.70 |
| copper | 3.49 | 17.7 | 5.08 |
| concrete | 22.2 | 78.1 | 3.52 |
| water | 49.9 | 171 | 3.43 |
| aluminum | 19.6 | 69.5 | 3.55 |
A single energy would give 3.32. Spectrum and attenuation ratios.
12 alpha lines, strongest 5.716 MeV
12 recorded lines from 5.283 to 5.871 MeV, the strongest 5.716 MeV at 51.2% of 98.98% total alpha emission.
| Energy (MeV) | Emission probability (%) |
|---|---|
| 5.7162 | 51.2 |
| 5.6067 | 25 |
| 5.5398 | 8.9 |
| 5.7470 | 8.9 |
| 5.4336 | 1.8 |
| 5.5016 | 1 |
| 5.8713 | 1 |
| 5.4240 | 0.39 |
| 5.8575 | 0.31 |
| 5.2873 | 0.2 |
Activity over weeks and months
Ten half-lives is 114 days — for Ra-223 itself, a storage problem rather than a disposal one, since those ten half-lives already take it below 0.1% of today's activity. The mean life 1/λ is 16.5 days.
| Elapsed | Fraction remaining |
|---|---|
| 1 half-life | 50.0 % |
| 2 half-lives | 25.0 % |
| 5 half-lives | 3.13 % |
| 10 half-lives | 0.0977 % |
| Time to fall to 10 % of today's activity | 38.0 days |
| Time to fall to 1 % | 75.9 days |
| Time to fall to 0.1 % | 114 days |
Limits of these dose rates
- Alpha reaches nothing through skin — Ra-223's alpha is an intake problem, not an external one.
- Model limits and internal dose.
Gamma and decay calculators for Ra-223
Other Radium nuclides: Ra-224, Ra-226, Ra-228
Computed from the IAEA Nuclear Data Section — Livechart API (ENSDF) and the NIST X-Ray Mass Attenuation Coefficients. Derivations and citations.